logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
    • 30 DEC 2015

    PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs

    SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the

    Read more →
    • Posted in
    • News
    • 15 DEC 2015

    PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program

    SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media

    Read more →
    • Posted in
    • News
    • 07 DEC 2015

    PharmaCyte Biotech Provides Update on Malignant Ascites and New Colon Cancer Studies

    SILVER SPRING, Md., Dec. 07, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued an update on the preclinical studies that are designed to determine the effectiveness of the Cell-in-a-Box® plus ifosfamide therapy

    Read more →
    • Posted in
    • News
    • 04 DEC 2015

    PharmaCyte Contractor Chamow & Associates to Visit Cell-in-a-Box® Encapsulation Facility in Bangkok, Thailand

    SILVER SPRING, Md., Dec. 04, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that representatives from Chamow & Associates, the San Francisco Bay Area firm contracted to assist PharmaCyte in preparing the

    Read more →
    • Posted in
    • News
    • 24 NOV 2015

    PharmaCyte Biotech Provides Link to Orphan Drug Designation for Its Pancreatic Cancer Treatment

    SILVER SPRING, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the European Commission has updated its website to reflect that PharmaCyte Biotech Europe Limited, a subsidiary of PharmaCyte

    Read more →
    • Posted in
    • News
    • 19 NOV 2015

    PharmaCyte Biotech Appoints International Diabetes Expert to Its Scientific Advisory Board

    SILVER SPRING, MD, November 19, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte’s Scientific Advisory Board. Prof. Hammes is recognized

    Read more →
    • Posted in
    • News
    • 17 NOV 2015

    PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment

    SILVER SPRING, Md., Nov. 17, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, upon the recommendation of the European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation

    Read more →
    • Posted in
    • News
    • 11 NOV 2015

    PharmaCyte Biotech Scientific Advisory Board Member Named Clinical Director of Prestigious Boston Cancer Center

    SILVER SPRING, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Manuel Hidalgo, MD, PhD, an internationally respected oncologist and a member of PharmaCyte ’s Scientific Advisory Board, has

    Read more →
    • Posted in
    • News
    • 23 OCT 2015

    PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design

    SILVER SPRING, MD, October 23, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr.

    Read more →
    • Posted in
    • News
    • 21 OCT 2015

    PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer

    SILVER SPRING, Md., Oct. 21, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte’s treatment (Cell-in-a-Box®

    Read more →
    • Posted in
    • News
  • 1
  • 2
  • 3
  • ›
  • »